Last reviewed · How we verify
Tyrosine kinase inhibitors — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tyrosine kinase inhibitors (Tyrosine kinase inhibitors) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitors TARGET | Tyrosine kinase inhibitors | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tyrosine kinase inhibitors CI watch — RSS
- Tyrosine kinase inhibitors CI watch — Atom
- Tyrosine kinase inhibitors CI watch — JSON
- Tyrosine kinase inhibitors alone — RSS
Cite this brief
Drug Landscape (2026). Tyrosine kinase inhibitors — Competitive Intelligence Brief. https://druglandscape.com/ci/tyrosine-kinase-inhibitors. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab